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Prostate Cancer Supplementary Materials and Methods. Briefly, the patients were divided into three groups for assessment: (I) receiving medical treatment for dyslipidemia (n = 29); (II) baseline L/H ratio of 2.5 or more without medical treatment for dyslipidemia (n = 22); and (III) baseline L/H ratio of <2.5 without medical treatment for dyslipidemia (n = 49). Group III patients were also assessed using uni-and multivariate analyses to determine the associations between an increased L/H ratio and baseline variables.
Supplementary Table 1 shows the baseline characteristics of the patients in this study. Figure 1 shows the changes in serum lipid profiles and testosterone at baseline and after 3 and 6 months of follow-up in all enrolled patients. ADT significantly lowered testosterone levels. After 3 months of follow-up, total cholesterol (TC, P<0.001), HDL-C (P=0.010), and LDL-C (P=0.007) were significantly increased, while triglycerides and L/H ratio did not show significant changes in all patients. Supplementary Table 2 shows the results of patients in each group. TC, HDL-C, and LDL-C increased significantly after 6 months of ADT administration in each group of patients. The L/H ratio (mean±s.d.) increased significantly from 1.8±0.5 to 1.9±0.6 (P = 0.004) in Group III patients, while it did not change significantly in Group I and II patients. The L/H ratio increased to 2.5 or more in 7 of the 49 patients in Group III after 6 months of follow-up. The clinical predictors associated with an increased L/H ratio of 2.5 or more on uni-and multivariate analyses are summarized in Table 1 . Multivariate analysis revealed that HDL-C was an independent predictor of an increased L/H ratio of 2.5 or more after 6 months of follow-up (odds ratio: 1.13, P = 0.013).
LDL-C levels increased significantly in this study, even in patients who took lipid-lowering drugs, while HDL-C levels also increased significantly ( Supplementary Table 2 ). In our study, enrolled patients did not have new-onset CVD within 6 months of follow-up. Although the duration of follow-up might have been too short to investigate new-onset CVD after ADT, increased HDL-C levels might have offset the cardiovascular risk caused by increased LDL-C levels. The L/H ratio is considered to be a clinically useful marker of cardiovascular events, and an increased L/H ratio is associated with an increased risk of cardiovascular events; in particular, baseline L/H ratios above 2.5 are associated with an increased risk of cardiovascular events. 8 In this study, the L/H ratio showed a significant increase in Group III. This study is the first to show that there exist a group of patients who have a higher risk of a worsening L/H ratio within the initial 6-month follow-up period after ADT despite having favorable baseline serum lipid profiles. Moreover, this study is the first to suggest that HDL-C is an independent predictor of an increased L/H ratio of 2.5 or more after 6 months of follow-up. Although these relationships still remain controversial, hypercholesterolemia is reported to be associated with a shorter time to castration-resistant PCa (CRPC) after ADT and survival after treatment for CRPC. 9,10 From the viewpoint of not only cardiovascular risk but also cancer management, it seems to be very important to aggressively manage dyslipidemia with the use of statins after initiation of ADT in patients with PCa.
Clinicians should pay attention not only to patients receiving medical treatment for dyslipidemia or with an L/H ratio of 2.5 or more but also to patients with an L/H ratio of <2.5. This study shows that patients with a baseline L/H ratio of <2.5 have a risk of worsening L/H ratio, although they seem to be "good lipid metabolism patients. " Clinicians can identify and manage PCa patients with a greater risk of worsening serum lipid profiles after ADT more effectively.
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SUPPLEMENTARY MATERIALS AND METHODS

Data collection
The data of 100 patients were analyzed. The following agents were used as ADT at the discretion of each urologist: 47 patients received goserelin subcutaneously in combination with oral bicalutamide 80 mg daily; 40 patients received leuprorelin subcutaneously in combination with oral bicalutamide 80 mg daily; and 13 patients received only degarelix subcutaneously.
The following baseline and follow-up variables were collected from medical records: age, body mass index (BMI), systolic, diastolic, and mean blood pressures (BPs), comorbidities, and clinical laboratory data. Comorbidities included hypertension, diabetes mellitus, dyslipidemia, and CVD. Clinical laboratory data included prostate-specific antigen (PSA), testosterone, HbA1c, triglycerides, total cholesterol (TC), HDL-C, LDL-C, L/H ratio, and C-reactive protein.
Statistical analysis
The results are reported as mean (± standard deviation). First, the changes in serum lipid profiles and testosterone among baseline and 3 and 6 months of follow-up measurements were compared in all patients using ANOVA and Tukey's or Games-Howell tests (Figure 1) . Second, the patients were divided into three groups: (I) receiving medical treatment for dyslipidemia (n = 29); (II) baseline L/H ratio of 2.5 or more without medical treatment for dyslipidemia (n = 22); or (III) baseline L/H ratio of <2.5 without medical treatment for dyslipidemia (n = 49). The changes in serum lipid profiles were compared in each group using the paired t-test or the Wilcoxon signed-rank test between baseline and 6 months of follow-up. Finally, in Group III patients, univariate analyses were performed to assess the associations between an increased L/H ratio and baseline variables. Continuous parametric variables were compared using t-tests. Nonparametric variables were compared using Mann-Whitney U-tests. Categorical variables were compared using Chi-square tests or Fisher's exact test. After significant candidate variables were selected on univariate analyses, multivariate logistic regression analysis was carried out to identify clinical predictors associated with an increased L/H ratio. Significance was defined at the level of P < 0.05. All statistical analyses were carried out using SPSS Statistics 23 (IBM, Chicago, IL, USA). 
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